Health and Fitness

FDA Approves First Buprenorphine Implant for Treatment of Opioid Dependence

Expanded use and availability of medication-assisted treatment is a top priority of federal effort to combat opioid epidemic
Silver Spring, Maryland--(ENEWSPF)--May 26, 2016.  The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.

Until today, buprenorphine for the treatment of opioid dependence was only approved as a pill . . .

First Trustee Forum

First Mayoral Forum

Please follow & like us :)

ARCHIVES